Skip to main content
. 2021 Apr 15;9:656359. doi: 10.3389/fcell.2021.656359

FIGURE 1.

FIGURE 1

Upregulation of SCRIB predicts poor prognosis for patients with colorectal cancer. (A) The expression level of SCRIB in normal tissues (n = 51) and CRC tissues (n = 635) from The Cancer Genome Atlas (TCGA) database. (B) CRC patients (n = 499) with progression-free survival data in the TCGA database were included in the survival analysis. The population was divided into two groups according to the median expression level of SCRIB. (C) The stratified analysis of CRC patients was based on pathological type, stage, metastasis, and lymphatic invasion. The data were derived from TCGA. Due to the lack of patient data, the total number of stratified analyses is not consistent. (D) SCRIB expression in 60 paired CRC tissues and adjacent normal tissues. (E) The expression of SCRIB in eight pairs of CRC tissues (T) and adjacent normal tissues (N) was detected by western blot. (F) The expression of SCRIB in CRC tissue was assessed by immunohistochemical staining. Representative micrographs show high-level and low-level expression of SCRIB in tumour tissues and adjacent nontumorous tissues. Scale bar, 100 μm. (G) qRT-PCR showed the expression level of SCRIB in NCM460, LOVO, HCT116, SW620, DLD-1, and HT29 cells; western blot showed the protein level of SCRIB in these cell lines. *p < 0.05, **p < 0.01, and ***p < 0.001.